Free Trial
NASDAQ:CLDX

Celldex Therapeutics Q2 2023 Earnings Report

Celldex Therapeutics logo
$18.91 +0.51 (+2.77%)
Closing price 04:00 PM Eastern
Extended Trading
$18.90 -0.01 (-0.05%)
As of 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celldex Therapeutics EPS Results

Actual EPS
-$0.65
Consensus EPS
-$0.65
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Celldex Therapeutics Revenue Results

Actual Revenue
$0.27 million
Expected Revenue
$0.67 million
Beat/Miss
Missed by -$400.00 thousand
YoY Revenue Growth
N/A

Celldex Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Tuesday, August 8, 2023
Conference Call Time
7:00AM ET

Celldex Therapeutics Earnings Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
Celldex Therapeutics (CLDX) Projected to Post Earnings on Monday
See More Celldex Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celldex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celldex Therapeutics and other key companies, straight to your email.

About Celldex Therapeutics

Celldex Therapeutics (NASDAQ:CLDX), a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

View Celldex Therapeutics Profile

More Earnings Resources from MarketBeat